-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Metastatic Breast Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabiralizumab in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabiralizumab in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabiralizumab in Melanoma Drug Details: Cabiralizumab (CSF1R antibody) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986263 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986263 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986263 in Idiopathic Pulmonary Fibrosis Drug Details:BMS-986263 (ND-L02-s0201) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986263 in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986263 in Liver Cirrhosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986263 in Liver CirrhosisDrug Details:BMS-986263 (ND-L02-s0201) is under development for the treatment of non-alcoholic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Secukinumab in Tendon and Ligament Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Secukinumab in Tendon and Ligament Pain Drug Details: Secukinumab (Cosentyx, Zafrez, Fraizeron, Scapho Lyvi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNA-043 in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNA-043 in Osteoarthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LNA-043 in Osteoarthritis Drug Details:LNA-043 is under development for the treatment of osteoarthritis. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NXP-800 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NXP-800 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NXP-800 in Solid Tumor Drug Details:NXP-800 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-06835375 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-06835375 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PF-06835375 in Systemic Lupus Erythematosus Drug Details:PF-06835375 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Doxorubicin in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Doxorubicin in Solid Tumor report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Batoprotafib in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Batoprotafib in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Batoprotafib in Esophageal Squamous Cell Carcinoma (ESCC)Drug Details:batoprotafib (TNO-155) is...